406 related articles for article (PubMed ID: 7766631)
1. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives.
Tanizawa A; Kohn KW; Kohlhagen G; Leteurtre F; Pommier Y
Biochemistry; 1995 May; 34(21):7200-6. PubMed ID: 7766631
[TBL] [Abstract][Full Text] [Related]
2. Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Valenti M; Nieves-Neira W; Kohlhagen G; Kohn KW; Wall ME; Wani MC; Pommier Y
Mol Pharmacol; 1997 Jul; 52(1):82-7. PubMed ID: 9224816
[TBL] [Abstract][Full Text] [Related]
3. In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Pondarré C; Strumberg D; Fujimori A; Torres-León R; Pommier Y
Nucleic Acids Res; 1997 Oct; 25(20):4111-6. PubMed ID: 9321666
[TBL] [Abstract][Full Text] [Related]
4. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
5. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.
Pommier Y; Kohlhagen G; Kohn KW; Leteurtre F; Wani MC; Wall ME
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8861-5. PubMed ID: 7568032
[TBL] [Abstract][Full Text] [Related]
6. Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA.
Chourpa I; Riou JF; Millot JM; Pommier Y; Manfait M
Biochemistry; 1998 May; 37(20):7284-91. PubMed ID: 9585542
[TBL] [Abstract][Full Text] [Related]
7. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
8. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Hoki Y; Fujimori A; Pommier Y
Cancer Chemother Pharmacol; 1997; 40(5):433-8. PubMed ID: 9272121
[TBL] [Abstract][Full Text] [Related]
9. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.
Desai SD; Liu LF; Vazquez-Abad D; D'Arpa P
J Biol Chem; 1997 Sep; 272(39):24159-64. PubMed ID: 9305865
[TBL] [Abstract][Full Text] [Related]
10. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
14. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects.
Pourquier P; Pilon AA; Kohlhagen G; Mazumder A; Sharma A; Pommier Y
J Biol Chem; 1997 Oct; 272(42):26441-7. PubMed ID: 9334220
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Tomicic MT; Kaina B
Biochim Biophys Acta; 2013 Jan; 1835(1):11-27. PubMed ID: 23006513
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity.
Wadkins RM; Bearss D; Manikumar G; Wani MC; Wall ME; Von Hoff DD
Curr Med Chem Anticancer Agents; 2004 Jul; 4(4):327-34. PubMed ID: 15281905
[TBL] [Abstract][Full Text] [Related]
17. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
20. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells.
Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y
Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
